U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...

Truist Financial analyst Srikripa Devarakonda downgraded Merck & Company (MRK – Research Report) to a Hold yesterday and set a price target ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo. Opdivo is part of a class of drugs called ...

MSD acquires WuXi Vaccines' Dundalk facility with a €500 million investment, creating 1,000 new jobs across Ireland and ...

M-Trust – which is now in beta test release mode – is described by the company as a "cyber-physical trust platform." ...

“I am thrilled to join such an innovative company at the forefront of gene editing,” said Briggs Morrison, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR ...

WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland ...

Merck, a leading science and technology company, today launched a beta version of M-Trust™, a secure cyber-physical trust ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...

Merck (MRK) ended the recent trading session at $99.72, demonstrating a +0.59% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.55%.

The rising prevalence of diabetes is anticipated to drive the expansion of the semaglutide market in the coming years.